Amifostine: Mechanisms of action underlying cytoprotection and chemoprevention

Drug Metabolism and Drug Interactions

Volumn 16, Issue 4, 2000, Pages 237-279

  Grdina, D J ^a   Kataoka, Y ^a   Murley, J S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Amifostine; Chemoprevention; Cytoprotection; Mechanisms

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ACETYLCYSTEINE; AMIFOSTINE; AZACITIDINE; BIS[2 (3 AMINOPROPYLAMINO)ETHYL] DISULFIDE; CAPTOPRIL; CISPLATIN; COBALT 60; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); EDETIC ACID; GELATINASE B; GELATINASE INHIBITOR; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MATRIX METALLOPROTEINASE INHIBITOR; SPERMINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER; CELL PROTECTION; CHEMOPROPHYLAXIS; CHROMATIN STRUCTURE; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IONIZING RADIATION; MOUSE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; OXIDATION REDUCTION REACTION; RADIATION CARCINOGENESIS; RADIATION PROTECTION; REVIEW; STRUCTURE ACTIVITY RELATION; XEROSTOMIA;

EID: 0034520732     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2000.16.4.237     Document Type: Review

References (118)

1. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity
2. High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma
3. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants
4. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia
5. Improved hematopoiesis using amifostine in secondary myelodysplasia
6. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and antimutagenic mechanisms of action
7. The aminothiol WR-1065 protects T lymphocytes from ionizing radiation-induced deletions of the HPRT gene
8. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid
9. Protection against late effects of radiation by S-2-(3-aminopropylamino)-ethylphosphorothioic acid
10. Chemoprotection in anticancer therapy: The emerging role of amifostine (WR-2721)
11. Amifostine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector
12. Aminothiols
13. Radiation protectors: The unexpected benefits
14. Chemoprevention with WR-2721 and its metabolites
15. Cysteine protection against X irradiation
16. Protective mechanisms in ionizing radiation injury
17. Thiol uptake by Chinese hamster V79 cells and aerobic radioprotection as a function of the net charge on the thiol
18. Binding of radioprotective thiols and disulfides in Chinese hamster V79 cell nuclei
19. Mechanism of action of aminothiol radioprotectors
20. Dephosphorylation of WR-2721 to WR-1065 in vitro and the effect of WR-1065 and misonidazole in combination in irradiated cells
21. Hydrolysis of WR-2721 by mouse liver cell fractions
22. Radioprotectants
23. Protection of mouse bone marrow by WR-2721 after fractionated irradiation
24. WR-2721 modification of type II cell and endothelial cell function in mouse lung after single doses of radiation
25. Modification of the radiation response of the mouse kidney by misonidazole and WR-2721
26. Radioprotection by WR-2721 of gamma-irradiated rat parotid gland: Effect on gland weight and secretion at 8-10 days post irradiation
27. Protection of acute and late radiation damage of the gastrointestinal tract by WR-2721
28. Protection by WR-3689 against gamma-ray induced intestinal damage: Comparative effect on clonogenic cell survival, mouse survival, and DNA damage
29. Antimutagenic properties of WR-2721 and of a radioprotective mixture, ATP-AET-serotonin, with regard to X-ray induced reciprocal translocations in mouse spermatogonia
30. Protection of spermatogonial survival and testicular function by WR-2721 against high and low doses of radiation
31. Radioprotection of mouse skin by WR-2721 in single and fractionated treatments
32. Modification of radiation-induced carcinogenesis in mice by misonidazole and WR-2721
33. Guidelines for the administration of amifostine
34. Dosing considerations with amifostine: A review of the literature and clinical experience
35. Differential chemoprotection of normal and malignant tissues
36. Influence of WR-2721 on the efficacy of radiotherapy and chemotherapy of murine tumors
37. Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice
38. Radioprotection of two mouse tumors by WR-2721 in single and fractionated treatments
39. Radioprotection of mouse skin vasculature and the RIF-1 fibrosarcoma by WR-2721
40. Effect of tumor type, size, and endpoint on tumor radioprotection by WR-2721
41. Comparison of the protective effects of three phosphorothioate radioprotectors in the RIF-1 tumor
42. Efficacy testing of WR-2721 in Great Britain or everything is black and white at the Gray Lab
43. Redox competition and radiosensitivity: Implications for testing radioprotective compounds
44. Effect of the radioprotector WR2721 on the response of metastatic Lewis lung carcinoma colonies to alkylating agents
45. Effect of tumor size on S-2-(3-aminopropylamino)-ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide
46. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
47. Antimutagenic effects of amifostine: Clinical implications
48. Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide
49. Differential radioprotection of cultured human diploid fibroblasts and fibrosarcoma cells by WR-1065
50. WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells
51. Radiosensitivity of polyamine-depleted HeLa cells and modulation by the aminothiol WR-1065
52. Radioprotection of cells in culture by WR-2721 and derivatives: Form of the drug responsible for protection
53. Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines
54. Mechanism of the radioprotective action of chemical compounds on Escherichia coli cells
55. Radiation protection of E. coli strain by cysteamine in the presence of oxygen
56. Radioprotecting action of chemical compounds on gamma-irradiated yeast cells of various genotypes
57. Effect of the aminothiol (WR-1065) on radiation induced mutagenesis and cytotoxicity in two repair deficient mammalian cell lines
58. Varying levels of radioprotection from the effects of JANUS neutrons in repair deficient xrs-5 hamster cells treated with azacytidine
59. The effects of cycloheximide and WR-1065 on radiation induced repair processes: A mechanism for chemoprevention
60. Cancer chemoprevention: Principles and prospects
61. Epidemiology, prevention, and early detection of breast cancer
62. Chemopreventive properties and mechanisms of N-acetylcysteine. The experimental background
63. In vivo effects of N-acetylcysteine on glutathione metabolism and on the biotransformation of carcinogenic and/or mutagenic compounds
64. Second thyroid neoplasms after prophylactic cranial irradiation for acute lymphoblastic leukemia
65. Second lung cancers in patients after treatment for an initial lung cancer
66. The molecular pathogenesis of treatment-induced (secondary) leukemias: Foundations for treatment and prevention
67. Breast cancer and other second neoplasms after childhood Hodgkin's disease
68. Mutagenecity of cancer drugs-prediction of the risk of a second tumor and the use of a mutation test for monitoring improvement of drugs
69. The radioprotector WR1065 reduces radiation-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in V79 cells
70. Protection against cis-diamminedichloroplatinum cytotoxicity and mutagenecity in V79 cells by 2-[(aminopropyl)amino]ethanethiol
71. Protective effects of 2-[(aminopropyl)amino]ethanethiol against bleomycin and nitrogen mustard-induced mutagenecity in V79 cells
72. Protection by WR1065 and WR151326 against fission neutron-induced mutations at the HGPRT locus in V79 cells
73. The radioprotector WR2721 reduces neutron induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation
74. 2-[(Aminopropyl)amino]ethanethiol (WR1065) is anti-neoplastic and anti-mutagenic when given during Co-60 gamma ray irradiation
75. Effects of WR1065 and WR151326 on survival and neoplastic transformation in C3H10T1/2 cells exposed to TRIGA or JANUS fission neutrons
76. Inhibitory effects of WR2721 and cysteamine on tumor initiation in mammary glands of pregnant rats by radiation
77. Protection against radiation-induced mutagenesis in V79 cells by 2-[(aminopropyl)amino]ethanethiol under conditions of acute hypoxia
78. Protective effect of S-2-(3-aminopropylamino)ethyl phosphorothioic acid against induction of altered hepatocyte foci in rats treated once with gamma-radiation within one day after birth
79. In vivo protection by the aminothiol WR-2721 against neutron-induced carcinogenesis
80. Chemoprevention by WR-2721
81. Role of oxidants and anti-oxidants in the induction of AP-1, NFκB, and glutathione S-transferase gene expression
82. Expression of thymidine kinase messenger RNA and a related transcript is modulated by the radioprotector WR-1065
83. Promotion of cystine uptake and its utilization for glutathione synthesis induced by cysteamine and N-acetylcysteine
84. Radioprotective effect of combinations of WR-2721 and mercaptopropionylglycine on mouse bone marrow chromosomes
85. Redox control of enzyme activities by thiol/disulfide exchange
86. Radiation-sensitive tyrosine phosphorylation of cellular proteins: Sensitive changes to GSH content induced by pretreatment with N-acetylcysteine or 1-buthionine-S,R-sulfoximine
87. Redox signaling and the emerging therapeutic potential of thiol antioxidants
88. Activation of NFκB and elevation of MnSOD gene expression by thiol reducing agents in lung adenocarcinoma (A549) cells
89. Oltipraz stimulates the transcription of the manganese superoxide dismutase gene in rat hepatocytes
90. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway
91. Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine
92. Comparative effects of repeated parenteral administration of several chelators on the distribution and excretion of cobalt
93. Experimental chelation therapy in chromium, lead, boron intoxication with N-acetylcysteine and other compounds
94. Can N-acetylcysteine affect zinc metabolism when used as a paracetamol antidote?
95. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma
96. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats
97. Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS
98. Protection from cellular oxidative injury and calcium intrusion by n-(2-mercaptoethyl)-1,3-propanediamine, WR-1065
99. Interference of WR-2721 with magnesium metabolism: Mechanism of action
100. Matrix metalloproteinases and metastasis
101. Effects of spermine on formation of HGPRT-mutants induced by ethylmethanesulfonate, methylmethanesulfonate, and mitomycin C in V79 Chinese hamster cells
102. Competition for polyamine uptake into rat lung slices by WR-2721 and analogues
103. Possible association of radioprotective and chemoprotective aminophosphorothioate drug activity with polyamine oxidase susceptibility
104. Involvement of the polyamine transport system in cellular uptake of the radioprotectants WR-1065 and WR-33278
105. Thiol WR-1065 and disulfide WR-33278, two metabolites of the drug Ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage
106. Equilibrium dialysis studies of polyamine binding to DNA
107. Equilibrium dialysis studies of the binding of radioprotector compounds to DNA
108. Binding radioprotective thiols and disulfides in Chinese hamster V79 cell nuclei
109. Conformational changes in chromatin structure induced by the radioprotective aminothiol, WR1065
110. The effect of 2-[(aminopropyl) amino]enthanethiol on fission-neutron-induced DNA damage and repair
111. Effects of radioprotectors on DNA damage and repair, proteins, and cell cycle progression
112. Inhibition of topoisomerase II alpha activity in CHO K1 cells by 2-[(aminopropyl)amino]ethanethiol (WR1065)
113. Topological complexes between DNA and topoisomerase II and effects of polyamines
114. WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase 11α leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells
115. Further evidence that the radioprotective aminothiol, WR1065, catalytically inactivates mammalian topoisomerase II